Medical directoryActive ingredient
Fezolinetant
The first non-hormonal treatment licensed for moderate to severe menopausal hot flushes. It blocks the neurokinin 3 (NK3) receptor in the temperature-regulating centre of the hypothalamus. Liver function needs to be monitored regularly.
Institutional endorsement by Clínica Evolution
Medical guides
Starting hormone therapy at 60 or over: when it is reconsidered and what the alternatives are
ReadMenopause tablets: what actually exists and what needs a prescription
ReadSide effects when starting hormone therapy: what is normal in the first few weeks
ReadFezolinetant (Veoza): the new non-hormonal pill for hot flushes
ReadPerimenopause: what it is, when it starts and how long it lasts
Read
Keep reading
This entry is for information. Your case requires an individual medical assessment.